Ozempic Stomach Paralysis Lawsuit

If you follow the news, you've probably heard about the diabetes medication called Ozempic, along with similar drugs such as Mounjaro, Trulicity, and Wegovy. It's also hard to watch local television without seeing an advertisement for this popular prescription drug. The catchy jingle and happy people in the commercials depict healthy users enjoying everyday life.

Unfortunately, the truth is far from happy for some Ozempic users. By the end of 2021, more than 10,000 people complained about serious side effects after taking Ozempic. Most of those reports involved gallbladder issues, but now, a serious new concern has been linked to Ozempic — stomach paralysis.

Ozempic Class Action Lawsuit

A plaintiff filed the first Ozempic stomach paralysis lawsuit in August 2023 seeking compensation from the maker of Ozempic, Novo Nordisk, for the extreme medical issues one Ozempic user has suffered. We expect to see many more Ozempic stomach paralysis personal injury lawsuits in the coming months.

Ozempic Lawsuit Updates - April 2024

With the creation of an Ozempic Multi-District Litigation (MDL), the team at Dolman Law Group will be following the legal progress and keeping you informed about the important information you need to know if you are considering filing an Ozempic stomach paralysis claim.

"Every drug has at least two side effects: the one you know about, and another."

- Sir Henry Dale, Nobel Prize-winning pharmacologist.

April 24, 2024 - Defendants in Ozempic MDL Respond to Allegations

Novo Nordisk and Eli Lilly are pushing back against the claims in Ozempic Stomach Paralysis MDL. Specifically, they responded to claims that their diabetes medications, like Ozempic and Wegovy, are causing people to have severe stomach problems and failed to properly warn about the risks. The defendants argue that the plaintiffs will not be able to prove their case because diabetes can cause the same problems that the drugs are being accused of. However, they did not address why people who do not have diabetes, like the thousands of people taking the medication for weight loss, are still developing these gastrointestinal injuries.

The companies also addressed complaints about the amount of money they've spent on marketing these drugs for weight loss even though they are not FDA-approved for weight loss. They claim that doctors are already aware of the potential side effects and should have informed their patients.

Finally, the defendants claim that common stomach issues might be mistaken for similar symptoms that aren't actually caused by the drugs. However, since the case is only addressing people with serious, provable injuries, this response was seemingly unnecessary.

This case will come down to whether the attorneys for the plaintiffs can convincingly show that these drugs caused their clients health issues. We will have to wait for a Daubert hearing and bellwether trials to see what happens on that front.

April 9, 2024 - Novo Nordisk Pays Doctors $11 Million to Prescribe Ozempic, Three Digestive Side Effects Dominate Patient's Claims

Ozempic manufacturer Novo Nordisk reportedly paid more than $11 million to physicians who prescribe this drug and similar medications for weight loss. The money was earmarked for 457,000 meals and travel to places such as London, Orlando, Honolulu, and Paris. So, rather than spend that money on further research into the serious side effects users have reported, such as stomach paralysis, the drug maker is trying to expand the group of patients who receive Ozempic.

The three main medical concerns reported by Ozempic users in these lawsuits are:

• Gastroparesis (stomach paralysis)
• Illeus (when bowel movement stops) and
• Bowel obstruction

These conditions make it difficult for the patient to process food and waste through their body. Common symptoms include nausea, pain, constipation, bloating, vomiting, and, of course, weight loss.

March 14, 2024: First Hearing on Ozempic Stomach Paralysis Lawsuit Held in Philadelphia Today

In an important development in the ongoing legal case regarding Ozempic and its dangerous side effects, the first hearing of the class-action (MDL) lawsuit is taking place today in the Philadelphia federal court. This lawsuit—which has gained widespread attention, as I am sure you are aware—centers on allegations that the diabetes medication Ozempic has led to stomach paralysis in some patients. This dangerous issue is magnified by the fact that Ozempic has swept the country by storm, and it seems every other person is using it, most of them off-label, for rapid weight loss.

While the details of the case have been extensively covered on our website, today's hearing marks a pivotal moment in the Ozempic MDL Lawsuit.

The hearing being held in Philadelphia today is a critical step in determining the course of the lawsuit. It brings together plaintiffs, legal representatives, and stakeholders, where they will present preliminary arguments and evidence. This initial phase is crucial for setting the tone of the case and can often provide insights into the legal strategies that will be employed by both the defendants' and plaintiffs' lawyers.

Stay tuned to Dolman Law Group for further updates on the Ozempic case as we continue to monitor the proceedings closely.

March 1, 2024 - Ozempic Multidistrict Litigation Judge Sets First Court Date

The first status conference in the Ozempic Multidistrict Litigation (MDL) has been set for March 14, 2024. On that date, counsel for both sides will appear, and Judge Gene E.K. Pratter will preside over the federal cases involved in the MDL. We should learn more about how Judge Pratter intends to run the litigation and possibly receive a court timeline that will describe what we can expect going forward.

February 20, 2024 - Research Links Ozempic Use with Psychiatric Adverse Events as Well as Gastroparesis (Stomach Paralysis)

A new study published by Frontiers Journal has demonstrated an association between patients who use Ozempic and adverse psychiatric issues. We already knew about several possible dangerous physical side effects linked to Ozempic, and now we're learning about mental health problems as well.

Also, research published in the BMJ shows a greater likelihood of gastrointestinal problems in patients taking GLP-1 receptor agonist medications like Ozempic and Mounjaro. In fact, the greater the dosage, the more likely someone may experience problems such as gastroparesis. Mounjaro happens to be the highest, most potent GLP-1 drug currently on the market.

February 2, 2024 – Ozempic Lawsuit Officially an MDL 

The Judicial Panel on Multidistrict Litigation (JPML) has officially made the decision to consolidate Ozempic lawsuits into a single Multidistrict Litigation (MDL). This decision is a significant step forward for everyone affected by the horrible side effects of Ozempic.

By making the cases an MDL, the federal court will streamline the legal process, make the pre-trial proceedings more efficient, and hopefully lead to quicker resolutions for the victims of the defective drug.

This is a pivotal moment in the Ozempic lawsuit.

January 15, 2024 – Latest Ozempic Lawsuit Alleges Plaintiff Developed Severe Gastroparesis 

On January 9, an Ozempic user who developed gastroparesis filed suit against the drug’s manufacturer, Novo Nordisk. The plaintiff, Sandra Linney, accuses the Danish company of failing to warn her of the side effects caused by the notorious GLP-1 RA medication. 

At this point in time, nearly two dozen plaintiffs throughout the federal court system have sued either or both Novo Nordisk and Eli Lilly and Company, Mounjaro manufacturer, in the latest set of high-profile product liability litigation.

January 15, 2024 - Judge Tells Plaintiff Deadline to Modify Her Ozempic Stomach Claim Has Passed

The federal judge in charge of overseeing the Ozempic stomach paralysis claims has previously ruled that product liability claims relying on a breach of express warranty complaint pertaining to Novo Nordisk were not going to be included in the multidistrict litigation. For one plaintiff, this may be the end of her path to recover compensation.

She had cited an express breach of warranty as the basis for her Ozempic stomach paralysis lawsuit, but failed to update it before the end of the 30-day period Judge Cain had allocated. Although the subset of Ozempic stomach paralysis claims arguing Novo Nordisk’s liability based on the manufacturer’s breach of warranty was not substantiated in federal courts, the pharmaceutical company may still be responsible for failure to warn consumers about serious side effects.

January 10, 2024 - FDA Investigation Casts Doubt on Link Between Ozempic and Suicidal Ideation

The FDA maintains a portal, known as the FDA Adverse Event Reporting System (FAERS), where the public can submit information about adverse reactions or complications they have experienced as a result of using medications like Ozempic. Based on reports that patients had experienced suicidal ideation, hair loss, and other issues after being treated with GLP-1 receptor agonist drugs, the agency conducted an inquiry into the safety of these products. European pharmaceutical regulators have been performing a similar probe into these concerns.

An NIH-funded research study, with a considerable sample size of 240,618 people, found evidence that contradicts the existence of a causal relationship between semaglutide medications and suicidal thoughts. Researchers reported that patients who took semaglutide-based medications for weight loss purposes had a lower risk of experiencing suicidal ideation at 0.01%, as compared to the patients who used other types of weight loss medications who had a 0.04% risk.

While this does not disprove individual accounts of suicidal ideation related to semaglutide-based drugs, the FDA’s findings will hopefully provide some measure of reassurance to Ozempic users who already have to be concerned about developing severe gastrointestinal complications. The FDA can still decide to issue warnings about the risk of suicidal ideation if new evidence emerges. Regulators are still investigating reports of hair loss and aspiration connected to GLP-1 receptor agonist drugs like Ozempic, Mounjaro, and Wegovy.

January 8, 2024 - Defendant Drug Manufacturers Novo Nordisk and Eli Lilly & Co. Split Over Louisiana Court's Jurisdiction

An Ozempic lawsuit that was recently filed in Louisiana alleges Ozempic and Mounjaro (a similar drug) caused the plaintiff severe health problems, including extensive vomiting and even tooth loss. The defendants originally claimed they did not have sufficient contact with the state to allow a lawsuit in Louisiana.

This plaintiff, along with others who have been allegedly harmed by this category of drugs, is requesting the consolidation of all federal cases into a Multi-District Litigation (MDL). The proposed MDL would be based in Louisiana.

However, the defendants are split, with Novo Nordisk agreeing to the formation and location of an MDL in either Louisiana or California. Meanwhile, Eli Lilly does not want to be included because it is only named in 10 Ozempic and Mounjaro stomach paralysis lawsuits so far. If an MDL is formed, Eli Lilly suggests Indiana or North Carolina as the appropriate court system. We are optimistic that an MDL will be created by the Judicial Panel on Multidistrict Litigation (JPML) later this month.

December 11, 2023 – Novo Nordisk's Attempt to Dismiss Case in Lousiana Fails

Novo Nordisk Inc., the maker of Ozempic, asked a federal judge to dismiss a lawsuit that claims the drug inadequately warns about various side effects, including gastroparesis. Thankfully, the judge denied the motion and allowed the failure to warn claim to proceed. This decision is important because the failure to warn legal theory is a key legal argument in all pending Ozempic lawsuits.

As more dangerous side effects come to light, the mass tort lawyers at Dolman Law Group are expanding our client base. We currently are working with clients complaining of bowel obstruction, paralyzed stomach (gastroparesis), and intestinal obstruction.

December 8, 2023 - European Group Studies Whether Ozempic Use Can Lead to Suicidal Thoughts, Multi-District Litigation Motion Filed

The European Medicines Agency (EMA) is studying another possible side effect in patients who take diabetes and weight loss drugs like Ozempic. The EMA is investigating whether patients can develop an increased risk of suicidal thoughts and self-harm after taking these drugs.

The mass tort team at Dolman Law Group is well versed in the dangers of Ozempic side effects such as stomach paralysis, vomiting syndromes, and gallbladder issues. We will be closely watching any developments related to suicidal ideation and self-harm.

In the meantime, a group of injured plaintiffs has filed a motion in federal court to centralize all cases involving gastric problems related to using Ozempic, Wegovy, Mounjaro, and similar drugs.

This proposed Multi-District Litigation (MDL) would be located in the Western District of Louisiana. If the motion is granted, all federal Ozempic cases would be consolidated for discovery purposes to ensure consistent judicial rulings and evidence exchange.

December 7, 2023 - A Push to Consolidate Ozempic Lawsuits Into an MDL 

Attorneys representing individuals claiming they were not warned of severe stomach problems associated with GLP-1 agonists such as Ozempic and Wegovy are seeking to consolidate all lawsuits in one central location. A motion has now been filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all Ozempic, Wegovy, and Mounjaro lawsuits filed in Federal Courts all over the U.S. to the Western District of Louisiana. The lawsuits to date have been filed against Novo Nordisk (manufacturer of Ozempic and Wegovy) and Eli Lilly (Mounjaro and Trulicity). 

We support the motion to consolidate all lawsuits against Ozempic, Mounjaro, Trulicity, and Wegovy to the Western District of Louisiana to be heard by Judge James Cain. 

December 1, 2023 – Ozempic May Be Linked to Surgical Complications

Recent reports have raised concerns related to anesthesia and regurgitation during surgery for individuals using Ozempic. Why does this happen? Delayed stomach emptying and reduced gastrointestinal tract mobility, called gastroparesis, may play a role.

This led to an alert from the American Society of Anesthesiologists, advising against using Ozempic and similar medications on the day of elective surgery and discontinuing them at least seven days before the procedure. The FDA has also recognized these concerns, updating the labels of Ozempic and related drugs to include new warnings.

These developments highlight the importance of being informed about the potential complications associated with Ozempic. If you or a loved one has experienced stomach-related side effects, reach out to legal counsel for guidance.

November 6, 2023 - New Study Links Weight Loss Drugs to Increased Risk of Developing Serious Gastrointestinal Problems and Delayed Gastric Emptying, FDA Requires Ozempic Warning

A new study published in the Journal of the American Medical Association shows the risk of gastrointestinal problems is greater among patients using Glucagon-like peptide 1 (GLP-1) agonists. GLP-1 agonists were originally prescribed to treat diabetes but are now widely prescribed off-label for weight loss. Weight loss drugs like Ozempic and Wegovy contain GLP-1, and patients are now reporting severe stomach and intestinal issues after using these drugs.

In September, the FDA required the Ozempic label to add a warning about a greater risk of intestinal blockage and the obstruction of food or fluid in the colon. As the studies continue to show, these drugs can lead to serious digestive problems, and we expect a flood of Ozempic cases in the coming months.

We are continuing to see more adverse event reports related to the use of Ozempic and Wegovy.

October 4, 2023 - Ozempic Lawsuits Allege Failure to Warn

Although the MDL is still in the infant stages, the initial cases being filed are based on a similar legal theory: failure to warn. Basically, the plaintiffs claim the makers of Ozempic knew, or should have known, that their drug could cause severe digestive issues but failed to warn users about these potential issues. To prove this legal theory, the injured plaintiffs will need to provide scientific evidence linking Ozempic to the medical conditions they are facing. This evidence will be a key component of these lawsuits.

September 18, 2023 - Multi-District Litigation is on the Horizon for Ozempic Lawsuits

With seven cases of Ozempic stomach paralysis lawsuits pending, a multi-district litigation (MDL) has been created to organize and process the hundreds or thousands of cases expected to be filed in the coming months and years.

August 2, 2023 - First Ozempic Gastroparesis Lawsuit Filed in Louisiana

Jaclyn Bjorklund filed the first Ozempic stomach paralysis lawsuit in Louisana, alleging serious medical issues that were caused by taking Ozempic and then Mounjaro, a similar drug for weight loss. We believe a number of Ozempic lawsuits will be filed over the coming weeks. A proposed class action in British Columbia has been filed against Novo Nordisk. We expect the same to occur in the U.S. before the end of year.

July 2023 - Evidence Connects Ozempic and Stomach Paralysis

New evidence shows that patients who use Ozempic or Wegovy for weight loss purposes can experience serious gastrointestinal conditions such as gastroparesis, paralysis of the stomach, and cyclic vomiting syndrome. These potentially severe conditions have been linked to using Ozempic and Wegovy for an extended period of time at the high doses recommended for weight loss. Patients suffering from these debilitating conditions may face permanent and serious impacts on their lives.

Trust Dolman Law Group to Answer Your Ozempic Stomach Paralysis Lawsuit Questions

The team of Ozempic lawsuit lawyers at Dolman Law Group are on the cutting edge of Ozempic litigation and we are monitoring this situation closely. Our attorneys are reviewing cases and performing the research needed to build solid lawsuits on behalf of consumers who injected this potentially harmful drug into their bodies without knowing the life-changing trauma they might face.

If doctors prescribed you Ozempic (or other similar medications, including Wegovy, Mounjaro, or Rybelsus) and you experienced problems including severe vomiting, stomach or abdominal pain, or bloating, acid reflux, or other gastrointestinal issues, reach out today.

Our dedicated Ozempic lawyers can help you bring a lawsuit against the drug manufacturer to help recover your financial losses. Contact Dolman Law Group today for a free consultation to learn more.  Ozempic and Mounjaro are the most common medications utilized off label for weight loss. Both Ozempic and Mounjaro have been linked to severe gastroparesis. These medications have warnings that use of this drug "delays gastric emptying." This delay can grow worse and result in permanent problems. Unfortunately, the manufacturers of these medications such as Novo Nordisk and Eli Lilly and Company have neglected patient safety despite evidence of potential adverse events. 

We now have several clients who underwent stomach bypass surgery to relieve symptoms associated with gastroparesis. While gastroparesis is a known risk for individuals suffering from diabetes; it is alarming to find otherwise healthy individuals being diagnosed with such following the off label use of diabetes medications. We are noting consistent complaints of stomach pain combined with delayed gastric emptying in our clients who used Wegovy, Ozempic, and Mounjaro. This is often followed by severe gastrointestinal events such as excessive vomiting. Inevitably, the individual is diagnosed with severe gastroparesis. 

What Is Ozempic?

Originally developed to treat type 2 diabetes, Ozempic (generic name Semaglutide) is a GLP-1 Receptor Agonist Analog-Type drug. It increases the production and secretion of insulin to help control blood sugar within the body by mimicking a human hormone called incretin glucagon-like peptide-1, or GLP-1.  Wegovy is a similar medication with a higher level of Semaglutide developed for weight management and to treat obesity. Mounjaro (another weight loss drug), manufactured by Eli Lilly uses Tirzepatide, which is a GLP-1 receptor agonist which controls appetite and blood sugar.

While the FDA approved Ozempic in 2017, Novo Nordisk has failed to note gastroparesis in its warning label or prescription information. Individuals who use a GLP-1 weight loss drug have a substantially higher risk of bowel obstruction (a blockage that prevents food from moving through the intestinal tracks), gastroparesis, undigested food, and acute gallbladder disease.

With a weekly injection, Ozempic helps control type 2 diabetes by:

• Stimulating the secretion of insulin so the cells in the body can receive glucose during digestion, maintaining steady levels of blood sugar throughout the process.
• Increasing the time it takes for food to leave the stomach, which makes the person feel full and satisfied longer.
• Slowing the release of glucose as the food remains in the stomach, which also keeps blood sugar levels steady.
• Suppresses glucagon, which is a hormone that tells you when you're hungry. Lower glucagon levels delays the feeling of hunger. 
• Delays gastric emptying

Various studies have shown GLP-1 drugs like Ozempic work by affecting nerves within the stomach to slow the muscle contractions that normally occur during digestion. With fewer contractions, the food stays in the stomach longer. However, in some cases, the food remains so long it becomes a hardened mass or the person must vomit the food after days of holding it in their stomach. 

When the stomach muscles slow too much, or come to a stop, the person experiences stomach paralysis, a condition known medically as gastroparesis. The drug maker does not mention this extremely painful and dangerous potential side effect anywhere in the product information.

Isn't Ozempic FDA Approved?

The Food and Drug Administration (FDA) first approved Ozempic in 2017 as a way to treat diabetes. The drug was to be administered by injection with either a 0.5 mg or 1 mg dose each week. Since then, the FDA has given Ozempic approval for different conditions using different doses.

For example, in 2019, the FDA approved Ozempic's claim that it can reduce the risk of a major cardiovascular event in patients who already have a history of cardiovascular issues along with diabetes. 

Then in 2022, the FDA approved a higher dose of Ozempic (2 mg per dose) because clinical trials revealed as many as 73 percent of type 2 diabetic Ozempic users could achieve the American Diabetes Association's recommended level of less than 7 percent blood sugar levels by taking the drug. 

Throughout this time, Ozempic ads continued to claim how some users could lose weight while taking the drug. The medication's warnings listed some possible side effects, but never mentioned severe gastrointestinal conditions, including gastroparesis. This is what has caused some much controversy around Ozempic.

Possible Side Effects of Taking Ozempic

The initial side effects recognized and disclosed by the maker of Ozempic included:

• Inflammation of the pancreas (pancreatitis)
• Vision changes
• Kidney failure and other kidney problems
• Allergic reactions

We now understand the possible Ozempic dangers include:

• Gallstones
• Acute gallbladder disease (cholecystitis)
• Thyroid tumors or thyroid cancer
• Diabetic retinopathy
• Hypoglycemia (low blood sugar)
• Gastroparesis (stomach paralysis)
• Severe vomiting
• Excessive vomiting
• Gastrointestinal burning
• Other stomach problems

Gallbladder Concerns Linked to Ozempic Use

In 2022, after several medical studies linked Ozempic use to gallbladder problems, Novo Nordisk added a product warning about possible gallbladder issues. Meanwhile, many Ozempic users suffered serious gallbladder problems, which led to substantial financial losses. As a result, plaintiffs filed numerous Ozempic gallbladder lawsuits throughout the country. The most common Ozempic lawsuit relates to stomach paralysis, known as gastroparesis.

When Was Ozempic First Linked to Gastrointestinal Issues?

Medical studies from 2020 revealed that GLP-1 agonists like Ozempic could cause an adverse reaction and worsen diabetic gastroparesis symptoms in patients who already had this condition before taking the drug. Although doctors can't specifically say what causes gastroparesis, the Cleveland Clinic attributes approximately one-third of reported cases to uncontrolled diabetes. 

Further studies found evidence that the drug itself actually caused the problems by slowing or stopping the stomach muscles, leading to blockages within the small intestine and GI tract. Gastroparesis sufferers report feeling full after eating only a small amount of food, acid reflux, nausea, vomiting, pain and bloating in the stomach and lower GI area, and a loss of appetite. All of these symptoms lead to weight loss, although not in a healthy way. The weight loss is caused by what is essentially a paralyzed stomach.

Although these studies showed how GLP-1 agonists can worsen diabetic gastroparesis and specifically recommended against using GLP-1 agonist therapy for people who have had similar symptoms, Novo Nordisk never informed doctors about this potential problem and did not change its prescribing or dosage recommendations.

Most Recent News Reports and Studies

In July 2023, more stories emerged about Ozempic and Wegovy users' struggles with severe stomach problems such as gastroparesis. CNN released a thorough report about several Ozempic and Wegovy users who were diagnosed with gastroparesis after starting GLP-1 agonist medications. At that point, the FDA claimed that it could not conclusively determine whether the drugs caused gastroparesis, and did not require any actions on the part of Novo Nordisk.

In response to CNN's request for comments, Novo Nordisk stated, “Gastrointestinal (GI) events are well-known side effects of the GLP-1 class. For semaglutide, the majority of GI side effects are mild to moderate in severity and of short duration. GLP-1's are known to cause a delay in gastric emptying, as noted in the label of each of our GLP-1 RA medications. Symptoms of delayed gastric and stomach emptying such as nausea and vomiting are listed as side effects.”

While the product's prescribing information does warn about nausea, vomiting, and a delay in emptying the stomach, it mentions these concerns are only in reference to how the body may absorb other medications. Further clinical trials revealed that 44% of patients who took Wegovy experienced nausea, and almost 25 percent reported vomiting.  Both of these issues are common symptoms of gastroparesis.

Similar trials performed on Ozempic users showed approximately 20 percent of users reported nausea and 10 percent reported vomiting as regular side effects. (Ozempic contains the same semaglutide active ingredient as Wegovy, but Ozempic is administered at a lower dose.) These symptoms are consistent in Ozempic, Wegovy, and Mounjaro. Keep in mind these medications slow the emptying of the stomach. The FDA (Food and Drug Administration) has yet to comment on these anecdotal findings. However, with health insurance claims mounting as a result of Ozempic, Wegovy, and Mounjaro use, the medical community has taken notice.

Ozempic Manufacturer Continues to Profit With Weight Loss Claims

Although Ozempic is only FDA-approved for treating diabetes, Novo Nordisk continues to tout the drug's weight loss benefits in its advertising campaigns. As a result, more people are requesting the drug to help them lose weight, partly because of celebrities who spread their Ozempic weight loss success stories on social media. 

Doctors may prescribe Ozempic “off-label” for weight loss instead of the original intended purpose of treating diabetes. In early 2023, Ozempic joined the FDA's Drug Shortage List because of the huge demand from overweight people. This translates into a financial windfall for Novo Nordisk while users suffer serious medical complications, life-altering conditions, and extensive financial losses. Even if you have been prescribed a similar obesity medicine by a Bariatric Surgeon, we still recommend avoiding off-label use of diabetes drugs.

Use of Drugs Like Ozempic and Wegovy Expanding Rapidly for Weight Loss

Ozempic, Wegovy, and Saxenda belong to the GLP-1 class of medications that mimic natural hormones to control appetite. These drugs have a potential benefit in the diabetic health arena which affects up to 40 million Americans annually. However, recently the drug has been used for weight loss in a big way.

The global market for Ozempic and other similar drugs for weight loss is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications. Revenue for the medications could reach as high as $70 billion in the US alone.

If Ozempic wasn't mainstream before, it definitely is now; Jimmy Kimmel joking about A-listers using the drug during the 2023 Oscars proved this. Elon Musk and Amy Schumer have admitted to taking the weight-loss drug.

What Is the Legal Basis of the Ozempic Stomach Paralysis Lawsuit?

A 44-year-old woman in Louisiana filed the first Ozempic stomach paralysis lawsuit against Novo Nordisk (the maker of Ozempic) and Eli Lilly and Company (the maker of Mounjaro). The plaintiff took Ozempic for approximately one year but stopped in July 2023. Then she began taking Mounjaro for the same purpose.

In her lawsuit, the plaintiff claimed both drugs created severe gastrointestinal events that led to extreme vomiting and stomach pain. She also reports these issues hospitalized her on multiple occasions.

The complaint points out the prescribing information for both drugs does not disclose any risk of similar gastrointestinal events and does not warn about gastroparesis. The lawsuit is based on the manufacturers' inadequate warning, failure to warn, and breach of warranty. 

This first case only names the drug manufacturers as defendants.  We expect many more claims and lawsuits to follow against Ozempic and other GLP-1 drugs that could potentially include the drug distributors and retailers as defendants.

See If You Qualify for an Ozempic Lawsuit

When you suffer from gastrointestinal obstruction, gastroparesis, or gastrointestinal obstruction after using Ozempic, you may be able to get compensation for your damages. Contact Doman Law Group to see if you qualify. We will evaluate your current medical records, past documentation, and future medical needs to see if you are a good fit to file an Ozempic lawsuit. We are similarly investigating and handling claims relating to the use of Mounjaro and Wegovy.

Dolman Law Group Has Extensive Dangerous Drug Experience

The mass tort legal team at Dolman Law Group is currently involved in bringing dangerous drug cases, including representing clients in the Tylenol Autism Lawsuit, Tepezza Hearing Loss claims, Elmiron Vision Loss Lawsuits, Suboxone Tooth Decay, and EzriCare Eye Drop claims. At Dolman Law Group, we have the skills, experience, and resources needed to take on corporate drug makers and Big Pharma. Read our clients' stories to better understand how we advocate for injured consumers' rights and fight for the compensation they deserve. Also, take a look below for some of the most common questions we receive about Ozempic lawsuit issues.

Ozempic Stomach Paralysis Lawsuit FAQs

Dolman Law Group is the Best Choice For Your Ozempic Stomach Paralysis Lawsuit

Now that the first Ozempic lawsuit regarding gastroparesis is on file, we expect the floodgates have opened. With so many people requesting and taking this drug, hundreds if not thousands of Ozempic gastrointestinal lawsuits may follow. 

Our product liability attorneys have earned a solid reputation for fiercely protecting consumers who are injured by corporate giants that care more about their profit margin than keeping innocent people safe. If taking Ozempic, Wegovy, or other GLP-1 drugs injured you, reach out now for your free consultation. 

Call us at 833-552-7274 or fill out this simple online form today. We can explain your legal rights and the possible compensation you can pursue from these negligent drug makers.